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Abstract
Background: An apolipoprotein C1 gene promoter polymorphism (CGTT insertion at position -
317) is associated with familial dysbetalipoprotemia, cardiovascular diseases, and Alzheimer's
disease. Restriction site polymorphism (RSP) assays were previously established to detect this
polymorphism. In this study, we introduce an improved RSP assay to detect this polymorphism.
Methods: This method included newly designed primers and only one round of PCR amplification
which yields one short and specific APOC1 fragment followed by HpaI digestion. Briefly, It consists
of three steps: 1) one round of PCR amplification of DNA sample, 2) HpaI enzyme digestion of PCR
products, and 3) electrophoresis on an agarose gel to visualize the genotypes. This improved RSP
method was applied to genotype 92 human samples collected from The Johns Hopkins Hospital.
Results: The observed allele frequencies for H1 and H2 from 92 genotyped human subjects were
0.707 and 0.293 respectively. The H2 allele frequency in the black subjects (0.350) was significantly
(p = 0.024) higher than that in the white subjects (0.177). This method was more economical and
convenient than the methods previously reported to detect this mutation in the APOC1 gene.
Conclusions: This assay will be readily applied to screen large sample sizes for population studies
in a simple and cost effective way.
Background
Coronary artery disease (CAD) is the leading cause of
death in the western world. High concentrations of blood
cholesterol or triglycerides and low high density lipopro-
tein (HDL) are among independent risk factors to CAD
[1]. DNA sequence variations at several genes (APOE,
APOB and APOC3) have been implicated as genetic deter-
minants of plasma lipid levels [2]. APOC1 is a constituent
of triglyceride-rich lipoproteins and HDL. The APOC1
gene lies in a gene cluster containing APOE and APOC2
on chromosome 19. The presence of the Hpa I restriction
site (CGTT insertion at position -317) in the APOC1 pro-
moter has a significant effect on APOC1 transcription
[3,4]. In one population-based genetic association study,
this polymorphism was associated with lipoprotein me-
tabolism disorder [5]. Recently the association of APOC1
gene polymorphism with both late-onset Alzheimer's dis-
ease [6] and age-associated memory impairment [7] has
been reported. Protection from obesity and insulin resist-
ance also has been found in mice over expressing human
APOC1 [8].
Nillesen et al [9] first designed one step PCR method fol-
lowed by HpaI digestion genotyped this polymorphism.
Published: 12 November 2002
BMC Medical Genetics 2002, 3:13
Received: 9 September 2002
Accepted: 12 November 2002
This article is available from: http://www.biomedcentral.com/1471-2350/3/13
© 2002 Gao et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media 
for any purpose, provided this notice is preserved along with the article's original URL.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/13
Page 2 of 4
(page number not for citation purposes)
However, 22 to 24 nucleotides out of 26 nucleotides in
the 5'-upstream primer (5'-TTTGAGCTCGGCTCTTGA-
GACAGGAA-3') were identical to at least 9 different se-
quences from 9 different chromosomes, it yielded some
non-specifically amplified fragments by PCR, thus made it
difficult for the allele-calling. Later a two-step nested PCR
followed by HpaI digestion was developed to detect this
polymorphism [4]. However, these two rounds of PCR
amplification consume more reagents and need more
time and labor to perform, thus exacting higher cost com-
pared to one round of PCR amplification as reported here.
In this study, we designed a pair of new oligoes using the
computer to amplify a shorter and a unique fragment
(195 bp) of APOC1 gene promoter. Only one round of
PCR is needed to efficiently generate the enough and spe-
cific PCR product for the genotyping. Our new protocol
consists of only three steps: one PCR amplification, HpaI
digestion and agarose gel electrophoresis. It's much sim-
pler, less costly and more suitable for clinical diagnostic
tests. This improved RSP method was applied to genotype
92 human samples collected from the John Hopkins hos-
pital. Two alleles, H1 (APOC-I HpaI-negative) and H2
(APOC-I  HpaI-positive), were typed. Our genotype re-
sults, that the H1-allele frequency is 0.707 and the H2-al-
lele frequency is 0.293, are in good agreement with the
findings of Xu et al (1999)[4] and Hubacek et al [2]. This
new RSP assay should facilitate the screening of this mu-
tation in large populations and contribute to the under-
standing of the molecular mechanism underlying the
association of this mutation with a number of diseased
conditions.
Methods
Subjects
Umbilical cord blood was obtained from 92 subjects con-
sisting of 53 males and 39 females, who were born at The
Johns Hopkins Hospital. Among them, 30 were white
Caucasians, 60 were African Americans, and 2 were other
races. The samples were collected for The Johns Hopkins
Study on the Fetal Origin of Atherosclerosis directed by
Dr. Peter O Kwiterovich. Informed consents were ob-
tained from the parents of each subject.
DNA preparation
DNA was isolated from cord white blood cells by using
Easy-DNA Kit (Cat. No. K1800-01, Invitrogene,
Carlsband, CA) by following the manufacture's instruc-
tion. The amount of DNA in each sample was determined
by measuring the optical density at 260-nm wavelength
using a spectrophotometer (DU-640, Beckman Instru-
ment, Inc., Fullerton, CA). DNA samples were stored at -
80°C.
Design and synthesis of PCR primers
The primers were designed using Primer 3 software (Prim-
er 3, Ver.3, Whitehead Institute/MIT Center for Genome
Research) based on the published human apoC1 genomic
DNA sequence flanking the promoter region (GenBank
accession: M20902). The primer sequences are as follows:
5' sense, 5'-ATC GAT CAC GAC CCT CTC-3', which corre-
sponds to the nucleotide positions 38 to 55 (at -455 rela-
tive to the APOC1 gene start site); 3' antisense, 5'-TCC
CCC ACT CAG AAT GTA GC-3', which corresponds the
nucleotide positions 233 to 214 (at -260 relative to the
APOC1 gene start site). The 5' sense primer was the short-
ened version of the upstream internal primer published
by Xu et al. [4]. The primers were synthesized on an Ap-
plied Biosystems model 381A synthesizer in the DNA
Synthesis and Analysis Core Facility, The Johns Hopkins
University School of Medicine.
PCR amplification
PCR was carried out in 25 µl total volume containing 50
ng genomic DNA, 5 pmol of each primer, 0.2 mM of each
dATP, dTTP, dCTP and dGTP, 1.5 mM MgCl2, and 1.25 U
of Taq DNA polymerase (Cat. No. N808-0160, Perkin-
Elmer, Foster City, CA). Thermal cycling was done in a
Perkin-Elmer GeneAmp PCR System 9600 Thermal Cycler
with an initial 2 min denaturation at 94°C followed by 35
cycles of denaturing at 94°C for 30 sec., annealing at 60°C
for 30 sec., extending at 72°C for 1 min, and a final exten-
sion of 5 min at 72°C.
Genotyping
One third of the PCR product was digested with 5 U HpaI
(Cat. No. 105S, New England Biolabs, Inc. Beverly, MA)
for one and half hours in a 37°C water bath, followed by
Figure 1
Gel patterns of Hpa I polymorphism. Lane 1 shows the
homozygous H1/H1 genotype, lane 2 is heterozygous H1/H2
and lane 3 is homozygous H2/H2. Lane 4 is a 72- to 1,353-bp
DNA ladder.
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separation on a 2% agarose gel electrophoresis for 1 to 1.5
hours at constant voltage of 110 V. The gels were stained
by 0.5 ug/ml of ethidium bromide. The image was cap-
tured on the thermal paper using the Eagle Eye II Still Vid-
eo System (Stratagene, La Jolla, CA). The typical gel
patterns of HpaI polymorphism are shown in Fig. 1. Lane
1 shows the homozygous H1/H1 genotype, lane 2 is the
heterozygous H1/H2, and lane 3 is the homozygous H2/
H2. Lane 4 is X174 DNA-haeIII Digest DNA ladder (Cat.
No. 302-6S, Beverly, MA).
Statistical analysis
Statistical analysis with the Chi-square test was done using
SigmaStat (ver2.03, SPSS, Inc., Chicago, IL, USA). Yates
correction for continuity was used in calculating the test.
P < 0.05 was set to be significantly different.
Results
HpaI polymorphism in APOC 1 gene promoter
An example of the gel pattern of each genotype is present-
ed in Fig. 1. In the homozygous genotype H1/H1, where
HpaI recognition sites are absent, no digestion of the PCR
products occurs, and only one 195 bp band appears (lane
1). In homozygous genotype H2/H2, where HpaI recogni-
tion sites are present, the PCR products were completely
digested into two small fragments: 137 and 58 bp, respec-
tively (lane 3). In heterozygous genotype H1/H2, where
the HpaI recognition site of one allele (H1) is absent and
the HpaI recognition site of another allele (H2) is present,
one allele was not digested and another allele was com-
pletely digested, so that all three possible fragments ap-
pear: 195, 137 and 58 bp, respectively (lane 2). This new
protocol produces clear-cut results for genotypes.
Mutation frequency in the study group
92 USA subjects were genotyped (Table 1). The H1-allele
frequency is 0.707 and the H2-allele frequency is 0.293.
The observed heterozygosity was 0.370. The H1-allele fre-
quency in the white subjects is 0.823 and the H2-allele fre-
quency is 0.177. The H1-allele frequency in the black is
0.650 and the H2-allele frequency is 0.350. The H2 allele
frequency in the black subjects (0.350) was significantly
(p = 0.024) higher than that in the white subjects (0.177).
Discussion
An  HpaI restriction fragment length polymorphism
(RFLP) in the APOE-C1-C2 gene cluster on chromosome
19 was found to be strongly associated with familial dys-
betalipoprotemia (type III hyperlipoproteinemia). Smit
M et al first localized the polymorphic HpaI site of APOC1
gene promoter by using Southern blot analysis [10]. The
exact localization was determined by building a restric-
tion map of the APOE-C1-C2 gene cluster for the enzymes
EcoRI, BamHI, HindIII and SalI, then subcloning and se-
quencing the SacI fragment, which contains the HpaI site.
The  HpaI site variably present at -317 relative to the
APOC1 gene is produced by a 4-bp CGTT insertion [3].
This Southern blot method was valuable for the identifi-
cation of the HpaI polymorphism, but is not convenient
for a routine diagnostic purpose. One step PCR method
designed by Nillesen et al [9] in 1990 for genotyping
APOC1 HpaI polymorphism was not a convenient meth-
od because the 5'-upstream primer in its PCR reaction was
highly homologous to several other gene sequences and
generated some non-specifically amplified fragments,
thus made it difficult for the allele-calling. Later a two-step
nested PCR developed by Xu et al [4] exacted more rea-
gents, more time and labor to perform. In this study, we
designed a pair of oligoes to amplify a shorter and a
unique fragment (195 bp) of APOC1 gene promoter.
Only one round of PCR is needed to efficiently generate
the enough and specific PCR product for the genotyping.
Our new protocol consists of only three steps: one PCR
amplification,  HpaI digestion and agarose gel electro-
phoresis. It's much simpler, less costly and more suitable
for clinical diagnostic tests. This type of RSP methods has
been previously reported by our lab to detect other restric-
tion site polymorphisms in genes related to cardiovascu-
lar and inflammation diseases [11–13].
Table 1: APOC1 Gene Allele Frequency in 92 Human Subjects
Na H1-allele H2-allele Total allelesb
Total 92 130 (0.707) 54 (0.293) 184 (1.000)
White 30 51 (0.823) 11 (0.177) 62 (1.000)
Black 60 78 (0.650) 42 (0.350) 120 (1.000)
Pc = 0.024
a In the study group, 53 males, 39 females; 30 white Caucasians, 60 African Americans, 2 are other races whose allele frequencies were not calcu-
lated separately. b There are 48 people with the H1/H1 genotype: 26 are the black, 21 are the white and 1 is other race; 34 with H1/H2: 26 are the 
black, 7 are the white and 1 is other race; and 10 with H2/H2: 8 are the black and 2 are the white. The observed heterozygosity was 0.370 (34/92). 
c Black vs White.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/13
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We have applied this new RSP to detect the APOC1 HpaI
polymorphism in 92 human subjects (Table 1) derived
from The Johns Hopkins Study on the Fetal Origin of
Atherosclerosis. Our findings that the H1-allele frequency
is 0.707 and the H2-allele frequency is 0.293 are consist-
ent with the previous reports by Xu et al[4] who reported
that in their population the allele frequencies for H1- and
H2-allele were 0.72 and 0.27, respectively, and by Hu-
bacek et al[2] who found that the allele frequencies of
their population for H1- and H2-allele were 0.75 and
0.25, respectively. We found that the H2 allele frequency
in the black subjects (0.350) was significantly (p = 0.024)
higher than that in the white subjects (0.177). Xu et al[4]
also reported that the H2 allele frequency in the black sub-
jects (0.31) was higher than that in the white subjects
(0.24). The larger and more population studies are need-
ed to validate these observations.
Conclusions
Even until now, high throughput genotyping cores, which
are in most cases dependent on the expensive equip-
ments, are only available in major institutions and com-
mercial companies. This new RSP method is readily useful
in any individual lab. It will facilitate the screening of
APOC1 gene promoter HpaI polymorphism in large and
more populations and contribute to the understanding of
the molecular mechanism underlying the association of
this mutation with a number of diseased conditions.
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